Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Interventions: Drug: Cyclophosphamide; Biological: IRX-2; Biological: Nivolumab; Procedure: Surgery Sponsors: Emory University; Bristol-Myers Squibb; IRX Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials